Results from the IMmotion 150 clinical trial comparing atezolizumab with sunitinib
In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, [...]
Combination treatment with atezolizumab plus bevacizumab improves progression-free survival
Results from the IMmotion150 phase II clinical trial showed that [...]
Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer
A retrospective study conducted by researchers in the Czech Republic [...]
Alternative scheduling of sunitinib and new treatment for kidney cancer: ASCO 2017 update
The following video from Practice Update is an interview with [...]
Biomarkers predict kidney cancer treatment outcomes
Two recent studies presented at the American Society of Clinical [...]
Atezolizumab plus bevacizumab demonstrate encouraging results as first- or second-line treatment for advanced kidney cancer
The results of the IMmotion150 trial, a phase II trial looking [...]
Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer
In this video, Dr W. Marston Linehan, chief of the [...]
Promising clinical activities support combination immunotherapy for metastatic kidney cancer
The results of an open-label pilot study by researchers at [...]
Atezolizumab plus bevacizumab combination show promise for first-line kidney cancer treatment
Results from the IMmotion150 Phase 2 clinical trial, a global, [...]
VEGF/mTOR combination for non-clear cell kidney cancer
The combination of vascular endothelial growth factor (VEGF)-directed and mammalian [...]
